LEUKOCARE is a privately held clinical-stage biotechnology company founded in 2003 and headquartered in Martinsried/Munich, Germany.
LEUKOCARE licenses proprietary technologies for stabilization and protection of proteins and other biologics against chemical and physical stress to partners in the fields of biopharmaceutical, medical device, and diagnostic industries. LEUKOCARE also offers know-how and experience in collaborative product development to support incorporation of the Stabilizing and Protecting Solutions (SPS) into new products.
The benefits of applying LEUKOCARE’s SPS technologies are:
- Stabilizing biologics (e.g. proteins, vaccines) in pharmaceutical, medical device, and diagnostic applications. Many biological macromolecules are intolerant towards physical or chemical stress. LEUKOCARE’s physiological and sugar free SPS excipient platform extends shelf-life and decreases sensitivity during storage and distribution.
- Enabling terminal sterilization of biologics by irradiation or EtO. So far, many proteins and other biological macromolecules loose most or even all of their pharmacological activity when irradiated for sterilization purposes by beta or gamma irradiation. LEUKOCARE’s SPS technologies protect biologics against the destructive impact of irradiation. Avoiding aseptic production significantly reduces costs and increases product safety.
- Functionalizing surfaces (e.g. of medical or diagnostic devices) with biologics. Drug-device combination products are well established in various fields of therapeutic applications. Combining biologics with medical device surfaces, however, is a relatively novel field of research. LEUKOCARE offers research and development services during early planning and design (identifying pathways and effector molecules), prototyping and product development.
LEUKOCARE’s QM system is certified according to EN ISO 9001 and
EN ISO 13485.